Site Map Press Room Careers
Financial
Quarterly Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions

Unaudited Quarterly Results for the Quarter & Half year ended 30th September, 2003

(Rs. in Mio)
  Three Months Ended Six Months Ended Year ended

Particulars

 (Unaudited) (Unaudited) (Audited)
  30.09.2003 30.09.2002 30.09.2003 30.09.2002 31.03.2003
Net Sales/Income from Operations 3489.9 3048.4 6548.6 5520.8 11903.8
Other Income 47.9 34.8 104.3 66.6

240.5
Total Income 3537.8 3083.2 6652.9 5587.4 12144.3
Expenditure          
a. (Increase) / Decrease in Stock in Trade
-82.6 -120.5 -258.1 -186.7 -319.0
 b. Consumption of Raw Materials 2076.0 2089.7 4146.0 3711.7 7547.7
 c. Staff Cost 120.0 57.3 231.5 116.2 335.2
 d. Other Expenditure 804.8 630.0 1463.7 1150.2 2521.8
Total expenditure 2918.2 2656.5 5583.1 4791.4 10085.7
Profit Before Depreciation, Interest & Tax 619.6 426.7 1069.8 796.0 2058.6
Interest 99.6 92.1 159.6 220.1 425.9
Depreciation 83.9 43.3 154.6 82.6 231.8
Profit before taxation 436.1 291.3 755.6 493.3 1400.9
Provision for Taxation
a) Current Tax
b) Deferred Tax
c) Tax adjustments of previous years
66.5
48.1
--
63.0
23.1
--
136.4
67.2
--
108.0
29.1
--
253.0
112.1
4.4
Net Profit 321.5 205.2 552.0 356.2 1031.4
Paid-up Equity Share Capital 
(Face value Rs. 5/- per share) 3		 242.0 232.5 242.0 232.5 232.5
Reserves excluding Revaluation Reserves -- -- -- -- 5101.4
Earnings per share (Rs.) (not annualised) 3          
- Basic
6.83  4.61  11.80   8.06 22.73
-Diluted
6.78   4.61 11.69   8.06 22.73
Aggregate of non-promoters Shareholding 3          
a.Number of Shares     19383470  17828276 17860946 
b.Percentage of Shareholding     40.05   38.34 38.41 
Segmentwise Revenue Results and Capital Employed Under Clause 41 of the Listing Agreement

(Rs. in Mio)

Particulars

 Three months ended Six months ended Year ended
(Unaudited) (Unaudited) (Audited)
  30.09.2003 30.09.2002 30.09.2003 30.09.2002 31.03.2003
1. Segment Revenue          
a. Bulk Drugs & Drug Intermediaries
3360.9 3032.2 6366.1 5455.4 12179.1
b.Formulation 204.7 153.3 324.4 296.5 642.5
c.Research & Development -- -- -- -- --
Total 3565.6 3185.5 6690.5 5751.9 12821.6
Less: Inter segment revenue 70.4 133.1 128.6 213.0 859.3
Net Sales/Income from operation 3495.2 3052.4 6561.9 5538.9 11962.3
2. Segment Results Profit(+) / Loss(-) before tax and interest
         
a. Bulk Drugs & Drug Intermediaries
623.5 406.6 1052.0 768.8 1852.3
b.Formulation 19.2 18.9 33.9 30.2 97.1
c.Research & Development -57.0 -26.5 -98.7 -45.4 -129.4
Total 585.7 399.0 987.2 753.6 1820.0
Less:  (I) Interest (Net) 90.8 69.1 141.4 189.9 381.8
(ii) Other un-allocable expenditure 58.8 38.6 90.2 70.4 37.3
    net of unallocable income          
Total Profit before tax 436.1 291.3 755.6 493.3 1400.9
3. Capital Employed          
a .Bulk Drugs 8715.7 4899.0 8715.7 4899.0 7331.6
b.Formulation 1570.0 1266.9 1570.0 1266.9 1463.3
c.Research & Development 364.7 207.0 364.7 207.0 256.1
Total 10650.4 6372.9 10650.4 6372.9 9051.0
1. The above results were taken on record by the Board of Directors at their meeting held on 31st October 2003
2. On 4th September 2003, the Company allotted 9,50,000 equity shares of Rs.10/- each at a premium of Rs.216/- on conversion of share warrants issued earlier under preferential issue.
3. Consequent to subdivision of equity shares from Rs.10/- to Rs.5/- each, the share data has been reclassified based on face value of Rs.5/- each.
4. Investor complaints pending at the beginning of the quarter: Nil,  received: 133,resolved: 133 and lying unresolved at the end of the quarter: Nil
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 31.10.2003 Managing Director
Site Map Press Room Careers